RASSF1A independence and early Galectin-1 upregulation in PIK3CA induced hepatocarcinogenesis: new therapeutic venues
A. Scheiter, K. Evert, L. Reibenspies, A. Cigliano, K. Annweiler, K. Mueller, L.-M.-G. Poehmerer, T. Itzel, S. Materna-Reichelt, A. Coluccio, K. Honarnejad, A. Teufel, C. Brochhausen, F. Dombrowski, X. Chen, , K. Utpatel
This study shows that PIK3CA mutations drive hepatocarcinogenesis independently of RASSF1A status, with early Galectin-1 upregulation and synergistic therapeutic effects of PIK3CA and Galectin-1 inhibitors.
bioRxiv · Jun 15, 2021Pathology